Device Trial Radar · NCT07874048
CENTAURI Post-Market Clinical Registry
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- CardioFocusNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 14, 2026
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this post-market clinical registry is to collect realworld clinical experience across multiple European centers regarding the safety and efficacy of the CENTAURI System
Conditions
- Paroxysmal AF
Interventions
CENTAURI System in conjunction with commercially available ablation cathetersDevice
Pulsed Field Ablation using the CENTAURI System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety OutcomeTime frame: 24 months
- Efficacy Outcome Acute SuccessTime frame: at the end of the index ablation procedure
- Efficacy Outcome Chronic SuccessTime frame: 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.